{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T05:20:46Z","timestamp":1787721646316,"version":"build-2784847793"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Non-clear cell renal cell carcinoma (nccRCC) represents a heterogeneous group of malignancies with limited prospective data to guide systemic therapy. Immune-based combination regimens are increasingly used in this setting by extrapolation from clear cell RCC trials. Whether patient sex influences outcomes in metastatic nccRCC treated with first-line immunotherapy (IO)-based combinations remains unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This is a retrospective sub-analysis of the ARON-1 real-world study that included 256 patients with intermediate- or poor-risk metastatic nccRCC treated with first-line IO-based combinations across 56 centers in 17 countries between January 2021 and December 2024. Patients with favorable-risk disease were excluded. The primary objective was to compare overall survival (OS) and time on treatment (ToT) between male and female patients. Tumor responses were assessed per RECIST 1.1 criteria. Survival outcomes were estimated using the Kaplan-Meier method and compared with the log-rank test. Cox proportional hazards regression models were used for univariable and multivariable analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 256 patients included, 197 (77%) were male and 59 (23%) were female. The median OS in the overall population was 27.8 months (95% CI 22.6\u201336.5), with a 1-year OS rate of 80%. No statistically significant difference in OS was observed between females and males (31.9 months vs 26.7 months; p = 0.124). In the intermediate-risk subgroup, females demonstrated a longer median OS compared with males (36.1 vs. 27.8 months; HR 0.60; p = 0.041). Among patients with liver metastases, median OS was not reached in females versus 15.0 months in males (1-year OS: 88% vs. 53%; p &amp;lt; 0.001). In patients with papillary histology, females showed a significantly longer OS than males (36.1 vs. 27.8 months; HR 0.52; p = 0.037).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this large real-world study of IO-based combinations in metastatic nccRCC, no statistically significant sex-based difference in OS was observed in the overall population. Exploratory subgroup analyses identified potential sex-based interactions in intermediate-risk disease, liver metastases, and papillary histology that warrant prospective investigation. The underrepresentation of women in this cohort and the retrospective design underscore the need for dedicated, sex-stratified analyses in future trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1911444","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T04:53:43Z","timestamp":1787720023000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Sex-based analysis of first-line immune-based combinations in intermediate\/poor-risk papillary, chromophobe, and unclassified renal cell carcinoma: an ARON-1 subanalysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Paola I.","family":"Valdez-Sandoval","sequence":"first","affiliation":[{"name":"Instituto Nacional de Ciencias M\u00e9dicas y Nutrici\u00f3n Salvador Zubir\u00e1n","place":["Mexico City, Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyn L.","family":"Beas-Lozano","sequence":"additional","affiliation":[{"name":"Instituto Nacional de Ciencias M\u00e9dicas y Nutrici\u00f3n Salvador Zubir\u00e1n","place":["Mexico City, Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zin W.","family":"Myint","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Markey Cancer Center, University of Kentucky","place":["Lexington, KY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Kucharz","sequence":"additional","affiliation":[{"name":"Department of Uro-Oncology, Maria Sklodowska-Curie National Research Institute of Oncology Warsaw","place":["Warsaw, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Mollica","sequence":"additional","affiliation":[{"name":"Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria Di Bologna","place":["Bologna, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Rizzo","sequence":"additional","affiliation":[{"name":"Struttura Semplice Dipartimentale (S.S.D.) Centro di Orientamento Oncologico (C.O.r.O.) Bed Management Presa in Carico, TDM, IRCCS Istituto Tumori \u201cGiovanni Paolo II\u201d","place":["Bari, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek","family":"Taha","sequence":"additional","affiliation":[{"name":"Royal Marsden National Health Service (NHS) Foundation Trust","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Landmesser","sequence":"additional","affiliation":[{"name":"Clinic of Urology","place":["L\u00fcbeck, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"P\u00e9rez Calabuig","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Complejo Hospitalario Universitario (CHU) Insular-Materno Infantil","place":["Las Palmas de Gran Canaria, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jawaher","family":"Ansari","sequence":"additional","affiliation":[{"name":"Medical Oncology, Tawam Hospital","place":["Al Ain, United Arab Emirates"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinzia","family":"Ortega","sequence":"additional","affiliation":[{"name":"Division of Oncology, Institute for Cancer Research and Treatment, Asl Cn2","place":["Alba-Br\u00e0, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravindran","family":"Kanesvaran","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, National Cancer Center Singapore","place":["Singapore, Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dipen","family":"Bhuva","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Army Hospital Research and Referral","place":["New Delhi, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anca","family":"Zgura","sequence":"additional","affiliation":[{"name":"Department of Oncology-Radiotherapy, Prof. Dr. Alexandru Trestioreanu Institute of Oncology, \u201cCarol Davila\u201d, University of Medicine and Pharmacy","place":["Bucharest, Romania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ondrej","family":"Fiala","sequence":"additional","affiliation":[{"name":"Department of Oncology and Radiotherapeutics, Faculty of Medicine, University Hospital in Pilsen, Charles University","place":["Pilsen, Czechia"]},{"name":"Biomedical Center, Faculty of Medicine in Pilsen, Charles University","place":["Pilsen, Czechia"]},{"name":"ARON Research Foundation Ente del Terzo Settore (ETS)","place":["Macerata, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Molina-Cerrillo","sequence":"additional","affiliation":[{"name":"ARON Research Foundation Ente del Terzo Settore (ETS)","place":["Macerata, Italy"]},{"name":"Department of Medical Oncology, Hospital Ram\u00f3n y Cajal","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiano","family":"Buti","sequence":"additional","affiliation":[{"name":"ARON Research Foundation Ente del Terzo Settore (ETS)","place":["Macerata, Italy"]},{"name":"Medical Oncology Unit, University Hospital of Parma","place":["Parma, Italy"]},{"name":"Department of Medicine and Surgery, University of Parma","place":["Parma, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Massari","sequence":"additional","affiliation":[{"name":"Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria Di Bologna","place":["Bologna, Italy"]},{"name":"ARON Research Foundation Ente del Terzo Settore (ETS)","place":["Macerata, Italy"]},{"name":"Department of Medical and Surgical Sciences (DIMEC), University of Bologna","place":["Bologna, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Fernanda","family":"Esparza-Orozco","sequence":"additional","affiliation":[{"name":"Instituto Nacional de Ciencias M\u00e9dicas y Nutrici\u00f3n Salvador Zubir\u00e1n","place":["Mexico City, Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Santoni","sequence":"additional","affiliation":[{"name":"ARON Research Foundation Ente del Terzo Settore (ETS)","place":["Macerata, Italy"]},{"name":"Medical Oncology Unit, Macerata Hospital","place":["Macerata, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria T.","family":"Bourlon","sequence":"additional","affiliation":[{"name":"Instituto Nacional de Ciencias M\u00e9dicas y Nutrici\u00f3n Salvador Zubir\u00e1n","place":["Mexico City, Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.34756","article-title":"Advances in non-clear cell renal cell carcinoma management: From heterogeneous biology to treatment options","volume":"154","author":"Wilson","year":"2024","journal-title":"Int J Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1177\/17562872241232578","article-title":"The incidence, pathogenesis, and management of non-clear cell renal cell carcinoma","volume":"16","author":"Naik","year":"2024","journal-title":"Ther Adv Urol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2025.02.020","article-title":"Renal cell carcinoma EAU guidelines on","volume":"87","author":"Bex","year":"2025"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2025.06.005","article-title":"Epidemiology of renal cancer: Incidence, mortality, survival, genetic predisposition, and risk factors","volume":"88","author":"Larcher","year":"2025","journal-title":"Eur Urol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/bju.12950","article-title":"Renal cell cancer histological subtype distribution differs by race and sex","volume":"117","author":"Lipworth","year":"2016","journal-title":"BJU Int"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2015.10.177","article-title":"Chromophobe renal cell carcinoma is the most common nonclear renal cell carcinoma in young women: Results from the SEER database","volume":"195","author":"Daugherty","year":"2016","journal-title":"J Urol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.4809","article-title":"Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor\u2013targeted agents: Results from a large, multicenter study","volume":"27","author":"Heng","year":"2009","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.10.049","article-title":"Everolimus versus sunitinib prospective evaluation in metastatic non\u2013clear cell renal cell carcinoma (ESPN): A randomized multicenter phase 2 trial","volume":"69","author":"Tannir","year":"2016","journal-title":"Eur Urol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01944","article-title":"Phase II trial of cabozantinib plus nivolumab in patients with non\u2013clear-cell renal cell carcinoma and genomic correlates","volume":"40","author":"Lee","year":"2022","journal-title":"J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2025.05.019","article-title":"First-line pembrolizumab plus lenvatinib for advanced non\u2013clear-cell renal cell carcinoma: Updated results from the phase 2 KEYNOTE-B61 trial","volume":"88","author":"Voss","year":"2025","journal-title":"Eur Urol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.annonc.2025.03.016","article-title":"Prospective randomized phase-II trial of ipilimumab\/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial","volume":"36","author":"Bergmann","year":"2025","journal-title":"Ann Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2016.90","article-title":"Sex differences in immune responses","volume":"16","author":"Klein","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2011.11.022","article-title":"The influence of sex and gender on the immune response","volume":"11","author":"Oertelt-Prigione","year":"2012","journal-title":"Autoimmun Rev"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/nri2394","article-title":"The X-files in immunity: Sex-based differences predispose immune responses","volume":"8","author":"Fish","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30261-4","article-title":"Cancer immunotherapy efficacy and patients\u2019 sex: A systematic review and meta-analysis","volume":"19","author":"Conforti","year":"2018","journal-title":"Lancet Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-0136","article-title":"Sex-based dimorphism of anticancer immune response and molecular mechanisms of immune evasion","volume":"27","author":"Conforti","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3390\/jcm7120542","article-title":"Effect of gender on the outcome of patients receiving immune checkpoint inhibitors for advanced cancer: A systematic review and meta-analysis of phase III randomized clinical trials","volume":"7","author":"Grassadonia","year":"2018","journal-title":"J Clin Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.5904","article-title":"Association of patient sex with efficacy of immune checkpoint inhibitors and overall survival in advanced cancers: A systematic review and meta-analysis","volume":"5","author":"Wallis","year":"2019","journal-title":"JAMA Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-024-03719-0","article-title":"Sex and survival outcomes in patients with renal cell carcinoma receiving first-line immune-based combinations","volume":"73","author":"Incorvaia","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"B25","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.clgc.2019.09.004","article-title":"Impact of patients\u2019 gender on efficacy of immunotherapy in patients with metastatic kidney cancer: A systematic review and meta-analysis","volume":"18","author":"Hassler","year":"2020","journal-title":"Clin Genitourin Cancer"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-023-04412-0","article-title":"Impact of sex on the efficacy of immune checkpoint inhibitors in kidney and urothelial cancers: A systematic review and meta-analysis","volume":"41","author":"Yanagisawa","year":"2023","journal-title":"World J Urol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"4565","DOI":"10.1200\/jco.2023.41.16_suppl.4565","article-title":"Gender disparities in metastatic RCC therapies and outcomes","volume":"41","author":"Gordon","year":"2023","journal-title":"J Clin Oncol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"4566","DOI":"10.1200\/jco.2021.39.15_suppl.4566","article-title":"Survival trends of men and women with metastatic clear cell renal cell carcinoma","volume":"39","author":"Grigg","year":"2021","journal-title":"J Clin Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-024-03876-2","article-title":"Sex differences in immunotherapy outcomes and tumor-infiltrating immune cell profiles in patients with advanced renal cell carcinoma","volume":"74","author":"Ishihara","year":"2025","journal-title":"Cancer Immunol Immunother"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0056667","article-title":"Estrogen inhibits renal cell carcinoma cell progression through estrogen receptor-\u03b2 activation","volume":"8","author":"Yu","year":"2013","journal-title":"PLoS One"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13571-x","article-title":"Sexual dimorphism and the role of estrogen in the immune microenvironment of liver metastases","volume":"10","author":"Milette","year":"2019","journal-title":"Nat Commun"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00701-6","article-title":"Androgen receptor increases hematogenous metastasis yet decreases lymphatic metastasis of renal cell carcinoma","volume":"8","author":"Huang","year":"2017","journal-title":"Nat Commun"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddab031","article-title":"Sexual dimorphism in cancer: Insights from transcriptional signatures in kidney tissue and renal cell carcinoma","volume":"30","author":"Laskar","year":"2021","journal-title":"Hum Mol Genet"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-66525-9","article-title":"Sex-specific survival gene mutations are discovered as clinical predictors of clear cell renal cell carcinoma","volume":"14","author":"Hwang","year":"2024","journal-title":"Sci Rep"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0140257","article-title":"Gender specific mutation incidence and survival associations in clear cell renal cell carcinoma (CCRCC)","volume":"10","author":"Ricketts","year":"2015","journal-title":"PLoS One"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13534","article-title":"Sex representation in clinical trials associated with FDA cancer drug approvals differs between solid and hematologic Malignancies","volume":"26","author":"Mendis","year":"2021","journal-title":"Oncologist"},{"key":"B37","doi-asserted-by":"publisher","first-page":"6521","DOI":"10.1200\/jco.2022.40.16_suppl.6521","article-title":"Representation of women in clinical trials supporting the FDA-approval of contemporary anticancer therapies","volume":"40","author":"Babcook","year":"2022","journal-title":"J Clin Oncol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.urology.2021.08.070","article-title":"Disparities in the treatment and survival of metastatic renal cell carcinoma","volume":"165","author":"Metcalf","year":"2022","journal-title":"Urology"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.8747","article-title":"Area vulnerability and disparities in therapy for patients with metastatic renal cell carcinoma","volume":"7","author":"Rahman","year":"2024","journal-title":"JAMA Netw Open"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1805104","article-title":"Real-world incidence of G3-G4 adverse events in patients with advanced renal cell carcinoma receiving immune-combinations (ARON-1)","volume":"17","author":"Beas-Lozano","year":"2026","journal-title":"Front Immunol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1911444\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T04:53:44Z","timestamp":1787720024000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1911444\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,26]]},"references-count":40,"alternative-id":["10.3389\/fonc.2026.1911444"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1911444","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,26]]},"article-number":"1911444"}}